Down Syndrome Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
Down Syndrome is a chromosomal disease
characterized by intellectual disability, a distinctive facial appearance, and
low muscle tone (hypotonia) in infancy. Although all affected people experience
cognitive delays, the intellectual disability is usually mild to moderate.
People with DS may have a variety of congenital disabilities. A heart defect
affects approximately half of all affected children. Digestive abnormalities,
such as intestine blockage, are less common. Individuals with DS are at a
higher risk of developing various medical conditions. These include
gastroesophageal reflux, a backflow of acidic stomach contents into the
esophagus, and celiac disease, a gluten intolerance. Trisomy 21
(nondisjunction) is the most ordinary type of Down syndrome, accounting for 95
percent of cases. Babies are typically born with 23 chromosome pairs (or 46
total chromosomes) in each cell, one inherited from the mother and father. In
Trisomy 21, an error in cell division is called “nondisjunction” this results
in a baby being born with an additional copy of chromosome 21, meaning there
are three copies of chromosome 21 instead of the usual two.
- The prevalence of Down Syndrome ranges from 80 to 91 cases
per 100,000 population in the USA
Thelansis’s “Down Syndrome Market
Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2021 To 2032" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Down
Syndrome treatment modalities options for eight major markets (USA, Germany,
France, Italy, Spain, UK, Japan, and China).
KOLs insights
of Down Syndrome across 8 MM market from the centre of Excellence/ Public/
Private hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
Down Syndrome Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment